Atlas Venture closed its oversubscribed $280 million Atlas Fund X, the firm’s first fund since becoming an exclusively life sciences-focused VC.

Atlas makes early stage investments in therapeutics developers, including platform companies and asset-centric or build-to-buy companies. The firm plans to seed four to six newcos a year over the next three to four years.